Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 1024-1029

  Sohn, Sang Kyun ^a   Oh, Suk Joong ^b   Kim, Byung Soo ^c   Ryoo, Hun Mo ^d   Chung, Joo Seop ^e   Joo, Young Don ^f   Bang, Soo Mee ^g   Jung, Chul Won ^b   Kim, Dong Hwan ^b   Yoon, Sung Soo ^h   Kim, Ho In ^h   Lee, Hong Ghi ⁱ   Won, Jong Ho ^j   Min, Yoo Hong ^k   Cheong, June Won ^k   Park, Joon Seong ^l   Eom, Ki Seong ^m   Hyun, Myung Soo ⁿ   Kim, Min Kyoung ⁿ   Kim, Hawk ^o   Park, Moo Rim ^p   Park, Jinny ^q   Kim, Chul Soo ^r   Kim, Hyeoung Joon ^s   Kim, Yeo Kyeoung ^s   Park, Eun Kyung ^t   Zang, Dae Young ^u   Jo, Deog Yeon ^v   Moon, Joon Ho ^a   Park, Seon Yang ^h   more..

^a Kyungpook National University Hospital   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Catholic University of Daegu   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Seoul National University Bundang Hospital   (South Korea)

^h Seoul National University Hospital   (South Korea)

ⁱ Konkuk University School of Medicine   (South Korea)

^j Soonchunhynag University Hospital   (South Korea)

^k Yonsei University College of Medicine   (South Korea)

^l Ajou University School of Medicine   (South Korea)

^m The Catholic University of Korea   (South Korea)

ⁿ Yeungnam University Hospital   (South Korea)

^o University of Ulsan College of Medicine   (South Korea)

^p Wonkwang University Hospital   (South Korea)

^q Gachon University   (South Korea)

^r Inha University Hospital   (South Korea)

^s Chonnam National University   (South Korea)

^t Chung Ang University College of Medicine   (South Korea)

^u Hannlym University Medical Center   (South Korea)

^v Chungnam National University College of Medicine   (South Korea)

more..

Author keywords

Chronic myeloid leukemia; cytogenetic response; imatinib; molecular response; trough blood level

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY SURFACE; CANCER DIAGNOSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; LOGISTIC MODELS; MALE; NEUTROPENIA; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TIME FACTORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957452443     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.563885     Document Type: Article

References (21)

1. Kantarjian HM, Cortes JE, OBrien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101:97-100. (Pubitemid 36025893)
2. Druker BJ, Guilhot F, OBrien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417. (Pubitemid 44903745)
3. Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004;9:259-270. (Pubitemid 38756875)
4. Kiguchi T, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res 2009;33:506-508.
5. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698. (Pubitemid 36077594)
6. Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006;57:145-164. (Pubitemid 43140744)
7. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880. (Pubitemid 32743979)
8. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96: 1070-1079. (Pubitemid 30616875)
9. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373. (Pubitemid 36304670)
10. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158-162. (Pubitemid 38114314)
11. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-894. (Pubitemid 41252840)
12. Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998;92:574-588. (Pubitemid 28323721)
13. Titier K, Picard S, Ducint D, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography- tandem mass spectrometry. Ther Drug Monit 2005;27: 634-640. (Pubitemid 41437643)
14. Hughes TP, Kaeda J, Branford S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. N Engl J Med 2003;349:1423-1432. (Pubitemid 37211057)
15. Kantarjian HM, Smith TL, OBrien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995;122: 254-261.
16. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-3499. (Pubitemid 46572540)
17. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronicphase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-4028.
18. Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 2009;33:271-275.
19. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-5411.
20. Sakai M, Miyazaki Y, Matsuo E, et al. Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol 2009; 89:319-325.
21. Horikoshi A, Takei K, Sawada S. Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML). Leuk Res 2007;31:574-575. (Pubitemid 46210044)